Novartis' Q4 earnings clouded by regulatory setbacks on inclisiran, Zolgensma

When Novartis CEO Vas Narasimhan hops on the phone with investors at 8 a.m. Tuesday, he will do so with his company already 4 points in the red.

The culprit? Regulatory delays and setbacks that have impeded two of the Swiss pharma’s major new drugs and made for a rocky Q4 report.